linjc16/ctgov huggingface dataset:
Acupuncture for Anxiety in Women With Breast Cancer: A Feasibility Study

Study Overview
=================
Brief Summary
-----------------
To assess the efficacy of acupuncture treatment in reducing symptoms of anxiety in women recently diagnosed with cancer. • To assess the efficacy of acupuncture treatment on improving perceived quality of life in women recently diagnosed with cancer.

Detailed Description
-----------------
This is a feasibility study of acupuncture for anxiety reduction in women with breast cancer. Ten patients will be recruited at the UNM Cancer Research Treatment Center via the Breast Clinic and screened for anxiety. Treatment will consist of 10 acupuncture sessions over 5 weeks. Measures (Hopkins Symptom Checklist, Sheehan Disability Index) will be administered and analyzed for treatment effect on scores.

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Procedure: Accupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Woman age 18 years or older excluding the need for parental/guardian permission. Histologic diagnosis of breast cancer. Having a minimum anxiety score of 1.75 on the Hopkins Symptom Checklist (HSCL) with sufficient English language proficiency for the investigators to make this determination. Able to give informed consent. Willingness to participate in the study and receive 10 acupuncture treatments in 5 weeks. Ability to fill out questionnaires and communicate with the research staff Exclusion Criteria: Males with breast cancer Psychoses or a major personality disorder Current use of opiates,

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Accupuncture|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients

Study Overview
=================
Brief Summary
-----------------
The study will evaluate the safety and tolerability of ACR325 in Parkinson disease patients and evaluate the effect on levodopa induced dyskinesias.

Official Title
-----------------
Randomised, Double-blind, Placebo-controlled Study Evaluating Safety and Tolerability of ACR325 in Parkinson's Disease Patients, With Evaluation of the Effect on Levodopa Induced Dyskinesias as a Secondary Measure

Conditions
-----------------
Parkinson's Disease, Tolerability

Intervention / Treatment
-----------------
* Drug: ACR325
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of idiopathic Parkinsons disease according to the United Kingdom Parkinson's Disease Society brain bank diagnostic criteria Levodopa induced dyskinesia Exclusion Criteria: Previous surgery for Parkinson's disease Any current or history of heart condition or increased pro-arrhythmic risk Severe or ongoing unstable medical condition

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ACR325<br> | Drug: ACR325<br>* Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks<br>|
| Placebo Comparator: Placebo<br> | Drug: ACR325<br>* Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks<br>Drug: Placebo<br>* Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety and tolerability |  | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Parkinson's disease, Levodopa, Dyskinesia, ACR325
Crestor Versus Placebo in Subjects With Heart Failure

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to investigate if rosuvastatin, added on top of all other medicines prescribed to subjects with symptomatic systolic heart failure, reduces the combined endpoint of cardiovascular death or non-fatal myocardial infarction or non-fatal stroke (time to first event)

Official Title
-----------------
Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study With Rosuvastatin in Subjects With Chronic Symptomatic Systolic Heart Failure

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Drug: CRESTOR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic symptomatic systolic heart failure of ischaemic aetiology as judged by the investigator, optimal therapy for chronic symptomatic systolic heart failure according to the investigator Exclusion Criteria: Acute myocardial infarction within 6 months before randomization Treatment with any statin or other lipid lowering drug; or a medical condition that in the opinion of the investigator requires treatment with a statin or other lipid lowering drug

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: CRESTOR|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary objective of this study is to determine whether rosuvastatin reduces the combined endpoint of cardiovascular death or non-fatal myocardial infarction (MI) or non-fatal stroke (time to first event). |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The secondary objectives are to evaluate the effects of rosuvastatin on: |  |  | 
| Total mortality |  |  | 
| Any coronary event defined as the combined endpoint of sudden death or fatal or non-fatal MI or Percutaneous Transluminal Coronary Angioplasty (PTCA) or Coronary Artery Bypass Grafting (CABG) or defibrillation of ventricular fibrillation by an implant |  |  | 
| Cardiovascular mortality with cause-specific mortality for sudden death; fatal MI; and death from worsening heart failure |  |  | 
| Total number of hospitalizations for cardiovascular causes; for unstable angina; and for worsening heart failure |  |  |
PeriOperative Bridging - Perioperative Anticoagulation in the Setting of Recent Intracoronary Drug Eluting Stents

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if an intravenous (IV) antiplatelet medication is as safe and effective at preventing clot formation in your stented artery as compared in people who have stopped clopidogrel prior to surgery.

Detailed Description
-----------------
Stent thrombosis continues to be associated with a high rate of death or myocardial infarction. While this risk has been ameliorated through the use of the oral antiplatelet agent clopidogrel, there is a small but important subset of patients who will require discontinuation of clopidogrel due to unplanned or emergency surgery. These patients are exposed to a high risk of stent thrombosis during this time period. It is not known whether a strategy of intravenous antiplatelet therapy to bridge these patients is effective at preventing the morbidity related to stent thrombosis in the perioperative period. We intend to assess, in a prospective observational manner, the clinical course of patients who have undergone stent implantation less than 6 months prior to a surgical procedure requiring discontinuation of clopidogrel therapy and the efficacy of intravenous antiplatelet therapy to prevent morbidity related to stent thrombosis.

Official Title
-----------------
Short-Term Outcomes of Perioperative Anticoagulation in the Setting of Recent Intracoronary Drug Eluting Stents

Conditions
-----------------
Stent Thrombosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18 years or greater, able to give consent DES implantation < or = 6 months prior to admission Undergoing an invasive surgical procedure that will require cessation of clopidogrel therapy for >48 hours Exclusion Criteria: Age < 18 years Refusal to give consent Surgical procedure performed without discontinuation of clopidogrel therapy (or < 48h of clopidogrel cessation) Ongoing anticoagulant therapy other than aspirin (i.e. warfarin, ticlopidine)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| stent thrombosis |  | hospitalization | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
drug eluding stents, perioperative bridging, Stents
Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the comparative efficacy of retinol 1.0% and tretinoin 0.02% in minimizing wrinkles, discoloration, roughness, and other signs of moderate to severe photodamage. Our hypothesis is that both products will be of comparable benefit.

Official Title
-----------------
Double-blinded, Single-center, Parallel-arm Comparison Study of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage

Conditions
-----------------
Photodamaged Skin, Wrinkles

Intervention / Treatment
-----------------
* Drug: Retinol
* Drug: Tretinoin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 35 or over Moderate to severe photodamage Exclusion Criteria: History of facial cosmetic surgery, facial resurfacing procedures, deep peels, or facial fillers History of keloids or hypertrophic scars Use of oral steroids or oral retinoids (such as Accutane) in past 6 months

Ages Eligible for Study
-----------------
Minimum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Retinol<br>Retinol 1.0% cream | Drug: Retinol<br>* 1.0% cream<br>|
| Active Comparator: Tretinoin<br>Tretinoin 0.02% cream | Drug: Tretinoin<br>* 0.02% cream<br>* Other names: Stieva-A;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Global Photodamage Severity | A photonumeric scale for the assessment of cutaneous photodamage (CE Griffiths, et al). Five photographic standards (en face and 45 degrees oblique) illustrating increasing severity of photodamage (min=0, max=8) where 0=no damamge; 2=mild damage; 4=moderate damage; 6=moderate/severe damage; and grade 8=severe damage. | Week 24 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Retinol, Tretinoin
Novel Use of an Adjustable Single 8-0 Polypropylene Suture of Scleral Fixation Without Conjunctival Dissection

Study Overview
=================
Brief Summary
-----------------
observe the effectivity of an adjustable single 8-0 polypropylene suture to scleral fix without conjunctival dissection for the treatment with aphakia or inadequate posterior capsule support. observe the complication of this surgery method.

Official Title
-----------------
Novel Use of an Adjustable Single 8-0 Polypropylene Suture of Scleral Fixation

Conditions
-----------------
Suture, Complication

Intervention / Treatment
-----------------
* Procedure: Novel use of an adjustable single 8-0 polypropylene suture of scleral fixation without conjunctival dissection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patients who used an adjustable single 8-0 polypropylene suture of scleral fixation without conjunctival dissection could be included. Exclusion Criteria: Data from patients with a < 6-month postoperative follow-up or with incomplete operative or postoperative medical records were excluded from this study. Enrolled patients had complete records pertaining to their visual acuity (VA), slit-lamp photographs, and ultrasound biomicroscope (UBM) findings.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| transscleral IOL fixation<br>the use of a novel adjustable single 8-0 polypropylene suture for scleral fixation without conjunctival dissection | Procedure: Novel use of an adjustable single 8-0 polypropylene suture of scleral fixation without conjunctival dissection<br>* The present study serves to describe a novel approach to utilizing a single adjustable 8-0 polypropylene suture for scleral fixation without conjunctival dissection and to evaluate safety and efficacy outcomes associated with this technique.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| uncorrected VA | preoperative and postoperative uncorrected VA | at 3 months postoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative complications | Postoperative complications during the follow-up | follow up time is larger 6 month |
Maintenance Gabapentin to Prolong Pregnancy.

Study Overview
=================
Brief Summary
-----------------
This is a pilot study to evaluate the tolerability and effects of maintenance gabapentin therapy on the rate of premature birth in women who have had preterm labor.

Official Title
-----------------
Effect of Maintenance Gabapentin Therapy on the Rate of Premature Birth in Women With Preterm Labor After Receiving Tocolysis.

Conditions
-----------------
Preterm Labor, Premature Birth

Intervention / Treatment
-----------------
* Drug: Gabapentin


Participation Criteria
=================
Eligibility Criteria
-----------------
Eligibility Criteria: Healthy 18-45 year old female with singleton pregnancy, 20-34 weeks gestation, without ruptured membranes. Preterm labor defined as regular uterine contractions of at least 6/hour for ≥ 1 hour with ≥ 1cm of cervical dilation or ≤ 2.5cm cervical length or any documented cervical change from the initial pelvic exam. Cervical dilation not more than 4cm. Initiation of a tocolytic agent (e.g. magnesium sulfate, nifedipine, indomethacin) within the previous 72 hours. Pregnancy not conceived through in-vitro fertilization (IVF) due to the known higher rates of congenital defects associated with this procedure.30 No placenta praevia or abruptio placentae or cervical cerclage. No intra-uterine growth restriction or non-reassuring fetal status. No known serious fetal malformations. No chorioamnionitis or medical/psychiatric/substance abuse comorbidity that may complicate the pregnancy or interfere with the subject's ability to comply with study procedures in the opinion of Dr. Guttuso or the subject's obstetrician. No history of suicide attempt. No suicidal thoughts over past 6 months. Not currently receiving gabapentin, pregabalin, progesterone or a known teratogenic medication and no known allergy to gabapentin therapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Gabapentin<br> | Drug: Gabapentin<br> <br> * Other names: Neurontin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of premature birth (before 37 weeks gestation) |  | At delivery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Preterm labor, premature birth, gabapentin
Influence of Serum Vitamin D Levels on Embryo Morphokinetic Parameters

Study Overview
=================
Brief Summary
-----------------
The aim of this study is observing the relation between serum Vitamin D levels and morphokinesis of time lapse monitored Day 5 embryo in between 18 and 38 years age women undergoing controlled ovarian hyperstimulation (COH) because of unexplained or tubal factor infertility. Individuals will be divided into 2 groups according to serum vitamin D levels as normal or low , and the influence of those levels in morphokinetic parameters of embryos will be identified.

Detailed Description
-----------------
Up to date there are few studies questioning the serum Vitamin D deficiency as a negative factor for pregnancy rates in women undergoing COH cycles and also are displaying different and inconclusive results. This dedicated negative affects may be mediated through endometrial and/or ovarial factors. In experimental animal models Vitamin D receptors have been found in endometrium and ovaries and deficient levels might have been a cause of impaired folliculogenesis. In one of human study Vitamin D has been suggested as a positive regulator of anti- Mullerian hormone (AMH) production. Therefore, we aimed to clarify the affects of Vitamin D on folliculogenesis, oogenesis and embryo quality in COH cycles by using time lapse monitoring.

Official Title
-----------------
Influence of Serum Vitamin D Levels on Embryo Morphokinetic Parameters in Women Undergoing Controlled Ovarian Hyperstimulation

Conditions
-----------------
Infertility

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years to 38 years age, 2 or less in vitro fertilization (IVF) / intracytoplasmic sperm injection (ICSI) attempt history, Unexplained or tubal factor infertility, Serum Follicle Stimulating Hormone (FSH) < 10, Antral Follicule Count (AFC)> 6-8 Exclusion Criteria: Male factor infertility, Presence of endometriosis or adenomyosis,Diminished ovarian reserve

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 38 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| vitamin D levels < 20ng/ ml<br>Vitamin D levels < 20ng/ ml | |
| vitamin D levels>20ng/ ml<br>Vitamin D levels >20ng/ ml | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to 2 pronucleus (PN) membrane breakdown, first cleavage and 3, 4, 5, 6, 7, and 8 cells stages, morula and blastocyst stage (t2, t3, t4, t5, t6, t7, t8, t Morula (M), t Blastocyst (B) ) |  | between 17 and 120 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Vitamin D, time lapse monitoring, embryo
Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy

Study Overview
=================
Brief Summary
-----------------
To obtain a genotypic analysis of patients with chronic exudative age-related macular degeneration noted to have subretinal or intraretinal edema despite continuous monthly Anti-VEGF therapy.

Official Title
-----------------
Genotypic Evaluation of Chronic Exudative Macular Degeneration Despite Monthly Anti-Vascular Endothelial Growth Factor (VEGF) Therapy

Conditions
-----------------
Wet AMD

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to provide written informed consent for participation in this study Subjects diagnoses of neovascular AMD who are on a monthly anti-VEGF regimen (have had >10 or more ranibizumab and/or bevacizumab injections within the last year) and who still have intra-retinal or subretinal fluid as confirmed by the Investigator Exclusion Criteria: Subjects with a Pigment Epithelial Detachment Exclusively Subjects with Serous Pigment Epithelial Detachments Subjects with history of the following: idiopathic polypoidal choroidal vasculopathy pathologic degenerative myopia central serous chorioretinopathy familial drusen adult onset foveal pattern dystrophy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Wet AMD Non-Responders to Anti-VEGF<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genetic analysis of patients with chronic wet age-related macular degeneration despite continuous anti-VEGF treatment |  | This is a one time only blood draw. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate demographic and clinical characteristics in patients treated with anti-VEGF therapy who fail to respond completely. |  | This is a one time only blood draw and assessment of clinical characteristics. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
wet AMD anti-VEGF, Genetic analysis of patients with Wet AMD who have not responded fully to anti-VEGF treatments